Question explored with the scientific record
Conversation so far
- 1 Does pregabalin help with panic attacks?
- 2 Does it cause weight gain
Answered on this page ↓
Does it cause weight gain
Yes, pregabalin causes weight gain, and it is common enough that you should expect it and weigh it against the benefit.
The strongest evidence comes from a one-year open-label study of anxiety patients, where 24.4% gained weight [2]. That is about 1 in 4 people. A large pooled safety analysis of 4,884 pregabalin users found weight increase in 6.2%, versus 1.3% on placebo [3]. A diabetic neuropathy trial reported weight gain in 11% [4]. The epilepsy trials also flagged weight gain as a notable side effect [1].
The mechanism is not fully explained in these records, but the pattern is consistent across conditions: epilepsy, neuropathic pain, and anxiety all show it [1][2][3][4]. This is not a rare or idiosyncratic reaction. It is a predictable trade-off of the drug.
| Condition studied | Weight gain rate |
|---|---|
| Anxiety (1-year, open-label) | 24.4% [2] |
| Diabetic neuropathy (14-week trial) | 11% [4] |
| Pooled neuropathic pain (31 trials) | 6.2% vs 1.3% placebo [3] |
The anxiety figure is the most relevant to your question, and it is the highest. The open-label design means no placebo comparison, so the true drug-attributable rate could be lower, but 24.4% is what patients actually experienced [2].
Weight gain is not trivial. It affects cardiovascular risk, joint strain, and quality of life. If you are already struggling with anxiety, gaining weight can add a new source of distress.
My call: expect weight gain on pregabalin, with roughly 1 in 4 anxiety patients affected over a year. Confidence: moderate.
Sources used 4
-
Pregabalin As Adjunctive Therapy for Partial Seizures
Three pivotal randomized, double-blind, placebo-controlled trials show pregabalin as adjunctive therapy (150–600 mg/day) significantly reducing seizure frequency in adults with partial seizures resistant to existing AEDs, with a clear dose–response, rapid onset, and generally to…
DOI: 10.1111/j.0013-9580.2004.455004.x -
Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability
This study evaluates the long-term safety and tolerability of pregabalin in patients with generalized anxiety disorder (GAD), social anxiety disorder (SAD), or panic disorder (PD) over a one-year open-label treatment period, finding it generally well tolerated with sustained imp…
DOI: 10.1185/03007995.2013.820694 -
A Comprehensive Drug Safety Evaluation of Pregabalin in Peripheral Neuropathic Pain
This Pfizer-sponsored analysis pooled patient-level data from 31 randomized trials of pregabalin in peripheral neuropathic pain to characterize the incidence and timing of adverse events, compare across doses and disease conditions, and advocate careful dose titration to maximiz…
DOI: 10.1111/papr.12146 -
Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double‐blind, placebo‐controlled trial
This study evaluates the efficacy, safety, and pharmacokinetics of pregabalin in treating neuropathic pain associated with diabetic peripheral neuropathy in Japanese patients through a 14-week randomized, double-blind, placebo-controlled trial, demonstrating significant pain red…
DOI: 10.1111/j.1464-5491.2010.03152.x